RxDoctor Payments Data

Jill Olson, MD

Neurology · Fort Collins, CONPI 1346446903

Payments from drug & device makers

$15,172in general payments, 2019–2025

Across 770 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Biogen$1K
  • Novartis$1K
  • AstraZeneca$1K
  • Amgen$897
  • Sanofi$836
  • plus $8K from 52 others

What the payments were for

  • Consulting fees$6254%
  • Speaking & faculty fees$8706%
  • Food & beverage$13,61090%
  • Education$670%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)138$2,168
Biogen54$1,324
Novartis81$1,218
AstraZeneca27$1,062
Amgen(2 entities)36$897
Sanofi8$836
EMD Serono, Inc.47$779
UCB, Inc.24$606
Mallinckrodt Hospital Products Inc.34$475
Lilly USA, LLC28$454
Teva Pharmaceuticals USA, Inc.33$377
Sunovion Pharmaceuticals Inc.22$373
Biohaven Pharmaceutical Holding Company Ltd.24$346
TG Therapeutics, Inc.5$320
Mallinckrodt Enterprises LLC24$290
Neurocrine Biosciences, Inc.12$268
Supernus Pharmaceuticals, Inc.13$264
Bristol Myers Squibb13$244
SK Life Science, Inc.10$224
GRT US Holding, Inc.11$207
Pfizer10$185
Amneal Pharmaceuticals LLC10$182
Biohaven Pharmaceuticals, Inc.9$178
MDD US Operations, LLC11$162
Acorda Therapeutics, Inc6$145
Neurelis, Inc.7$144
Eisai Inc.7$136
Medtronic1$111
Acadia Pharmaceuticals Inc4$83
Catalyst Pharmaceuticals, Inc.5$81
Johnson & Johnson5$78
Lundbeck LLC4$77
Argenx US, Inc.3$57
Avion Pharmaceuticals2$54
Greenwich Biosciences, Inc.2$53
Merz North America, Inc.2$50
Travere Therapeutics, Inc.4$48
Sumitomo Pharma America, Inc.4$47
Banner Life Sciences, LLC2$47
Merz Pharmaceuticals, LLC3$46
E.r. Squibb & Sons, L.L.C.2$45
Bausch Health US, LLC2$40
Adamas Pharmaceuticals, Inc.2$38
Tanabe Pharma America, Inc.2$37
Jazz Pharmaceuticals Inc.1$34
Arbor Pharmaceuticals, Inc.2$34
Akcea Therapeutics, Inc.2$29
Collegium Pharmaceutical, Inc.2$26
Genentech USA, Inc.1$24
Assertio Therapeutics, Inc.1$23
Octapharma USA, Inc.1$23
Abbott1$23
Saol Therapeutics Inc.1$21
Avanir Pharmaceuticals, Inc.1$18
Scilex Pharmaceuticals Inc.1$17
Averitas Pharma Inc.1$17
CSL Behring1$14
Upsher-smith Laboratories LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,172 in reported general payments places this provider in the 70th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado

Medicare billing

Part B allowed, 2024
$193,293
Medicare patients
226
Services billed
15,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone26$356,574
Rebif RebidoseInterferon Beta-1a/Albumin12$122,762
Kesimpta PenOfatumumab12$107,724
CopaxoneGlatiramer Acetate13$75,836
Emgality PenGalcanezumab-Gnlm64$68,913
Nurtec OdtRimegepant Sulfate45$52,968
UbrelvyUbrogepant30$37,027
BriviactBrivaracetam13$26,405
FycompaPerampanel13$23,041
EpidiolexCannabidiol (Cbd)14$21,732
Aimovig AutoinjectorErenumab-Aooe28$21,198
Emgality SyringeGalcanezumab-Gnlm11$7,122
Gabapentin283$6,967
Lamotrigine ErLamotrigine11$5,251
Carbidopa-Levodopa ErCarbidopa/Levodopa55$5,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$377$75,83613 claims
PfizerNurtec Odt$185$52,96845 claims
AbbVieUbrelvy$2,168$37,02730 claims
UCB, Inc.Briviact$606$26,40513 claims
Eisai Inc.Fycompa$136$23,04113 claims
Upsher-smith Laboratories LLCTopiramate$12$1,35781 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 334 neurology providers in Colorado.

Other neurology in Fort Collins

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →